Literature DB >> 30084836

The Epigenomic Landscape of Pituitary Adenomas Reveals Specific Alterations and Differentiates Among Acromegaly, Cushing's Disease and Endocrine-Inactive Subtypes.

Matthew P Salomon1, Xiaowen Wang1, Diego M Marzese1, Sandy C Hsu2, Nellie Nelson2, Xin Zhang1, Chikako Matsuba1, Yuki Takasumi3, Carmen Ballesteros-Merino4, Bernard A Fox4, Garni Barkhoudarian5,6, Daniel F Kelly5,6, Dave S B Hoon7,2,5.   

Abstract

Purpose: Pituitary adenomas are one of the most common benign neoplasms of the central nervous system. Although emerging evidence suggests roles for both genetic and epigenetic factors in tumorigenesis, the degree to which these factors contribute to disease remains poorly understood.Experimental Design: A multiplatform analysis was performed to identify the genomic and epigenomic underpinnings of disease among the three major subtypes of surgically resected pituitary adenomas in 48 patients: growth hormone (GH)-secreting (n = 17), adrenocorticotropic hormone (ACTH)-secreting (n = 13, including 3 silent-ACTH adenomas), and endocrine-inactive (n = 18). Whole-exome sequencing was used to profile the somatic mutational landscape, whole-transcriptome sequencing was used to identify disease-specific patterns of gene expression, and array-based DNA methylation profiling was used to examine genome-wide patterns of DNA methylation.
Results: Recurrent single-nucleotide and small indel somatic mutations were infrequent among the three adenoma subtypes. However, somatic copy-number alterations (SCNA) were identified in all three pituitary adenoma subtypes. Methylation analysis revealed adenoma subtype-specific DNA methylation profiles, with GH-secreting adenomas being dominated by hypomethylated sites. Likewise, gene-expression patterns revealed adenoma subtype-specific profiles. Integrating DNA methylation and gene-expression data revealed that hypomethylation of promoter regions are related with increased expression of GH1 and SSTR5 genes in GH-secreting adenomas and POMC gene in ACTH-secreting adenomas. Finally, multispectral IHC staining of immune-related proteins showed abundant expression of PD-L1 among all three adenoma subtypes.Conclusions: Taken together, these data stress the contribution of epigenomic alterations to disease-specific etiology among adenoma subtypes and highlight potential targets for future immunotherapy-based treatments. This article reveals novel insights into the epigenomics underlying pituitary adenomas and highlights how differences in epigenomic states are related to important transcriptome alterations that define adenoma subtypes. Clin Cancer Res; 24(17); 4126-36. ©2018 AACR. ©2018 American Association for Cancer Research.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30084836     DOI: 10.1158/1078-0432.CCR-17-2206

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  38 in total

1.  Mammosomatotroph and mixed somatotroph-lactotroph adenoma in acromegaly: a retrospective study with long-term follow-up.

Authors:  Liang Lv; Yong Jiang; Senlin Yin; Yu Hu; Cheng Chen; Weichao Ma; Shu Jiang; Peizhi Zhou
Journal:  Endocrine       Date:  2019-07-31       Impact factor: 3.633

2.  Alternative Lengthening of Telomeres (ALT) and Telomerase Reverse Transcriptase Promoter Methylation in Recurrent Adult and Primary Pediatric Pituitary Neuroendocrine Tumors.

Authors:  Hiba Alzoubi; Simone Minasi; Francesca Gianno; Manila Antonelli; Francesca Belardinilli; Felice Giangaspero; Marie-Lise Jaffrain-Rea; Francesca Romana Buttarelli
Journal:  Endocr Pathol       Date:  2022-01-06       Impact factor: 3.943

Review 3.  Aggressive pituitary tumours and pituitary carcinomas.

Authors:  Gérald Raverot; Mirela Diana Ilie; Hélène Lasolle; Vincent Amodru; Jacqueline Trouillas; Frédéric Castinetti; Thierry Brue
Journal:  Nat Rev Endocrinol       Date:  2021-09-07       Impact factor: 43.330

Review 4.  Genetics of Cushing's disease: from the lab to clinical practice.

Authors:  Marily Theodoropoulou; Martin Reincke
Journal:  Pituitary       Date:  2022-07-19       Impact factor: 3.599

5.  Global changes in chromatin accessibility and transcription in growth hormone-secreting pituitary adenoma.

Authors:  Meng Wang; Chenxing Ji; Yichao Zhang; Zhiqiang Zhang; Yu Zhang; Huiping Guo; Nidan Qiao; Xiang Zhou; Xiaoyun Cao; Zhen Ye; Yifei Yu; Vladimir Melnikov; Wei Gong; Min He; Zhaoyun Zhang; Yao Zhao; Xuelong Wang; Gang Wei; Zhao Ye
Journal:  Endocrine       Date:  2022-08-10       Impact factor: 3.925

Review 6.  Fluorescence guided surgery for pituitary adenomas.

Authors:  Nikita Lakomkin; Jamie J Van Gompel; Kalmon D Post; Steve S Cho; John Y K Lee; Constantinos G Hadjipanayis
Journal:  J Neurooncol       Date:  2021-02-21       Impact factor: 4.130

7.  Potential markers of disease behavior in acromegaly and gigantism.

Authors:  Laura C Hernández-Ramírez
Journal:  Expert Rev Endocrinol Metab       Date:  2020-05-06

8.  DNA methylation-based signatures classify sporadic pituitary tumors according to clinicopathological features.

Authors:  Maritza S Mosella; Thais S Sabedot; Tiago C Silva; Tathiane M Malta; Felipe Segato Dezem; Karam P Asmaro; Michael Wells; Abir Mukherjee; Laila M Poisson; James Snyder; Ana C deCarvalho; Tobias Walbert; Todd Aho; Steven Kalkanis; Paula C Elias; Sonir R Antonini; Jack Rock; Houtan Noushmehr; Margaret Castro; Ana Valeria Castro
Journal:  Neuro Oncol       Date:  2021-08-02       Impact factor: 12.300

Review 9.  Muti-omics integration analysis revealed molecular network alterations in human nonfunctional pituitary neuroendocrine tumors in the framework of 3P medicine.

Authors:  Siqi Wen; Chunling Li; Xianquan Zhan
Journal:  EPMA J       Date:  2022-02-17       Impact factor: 6.543

Review 10.  Research advances on the immune research and prospect of immunotherapy in pituitary adenomas.

Authors:  Ding Nie; Qiuyue Fang; Bin Li; Jianhua Cheng; Chuzhong Li; Songbai Gui; Yazhuo Zhang; Peng Zhao
Journal:  World J Surg Oncol       Date:  2021-06-05       Impact factor: 2.754

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.